NO891470L - Fremgangsmaate for fremstilling av nye substituerte azetidinoner. - Google Patents
Fremgangsmaate for fremstilling av nye substituerte azetidinoner.Info
- Publication number
- NO891470L NO891470L NO89891470A NO891470A NO891470L NO 891470 L NO891470 L NO 891470L NO 89891470 A NO89891470 A NO 89891470A NO 891470 A NO891470 A NO 891470A NO 891470 L NO891470 L NO 891470L
- Authority
- NO
- Norway
- Prior art keywords
- procedure
- preparation
- new substituted
- substituted azetidinones
- azetidinones
- Prior art date
Links
- 230000001796 anti-degenerative effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003602 elastase inhibitor Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Reinforced Plastic Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17968888A | 1988-04-11 | 1988-04-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO891470D0 NO891470D0 (no) | 1989-04-10 |
| NO891470L true NO891470L (no) | 1989-10-12 |
Family
ID=22657566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO89891470A NO891470L (no) | 1988-04-11 | 1989-04-10 | Fremgangsmaate for fremstilling av nye substituerte azetidinoner. |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0337549B1 (de) |
| JP (1) | JP2736113B2 (de) |
| KR (1) | KR930008223B1 (de) |
| CN (1) | CN1037144A (de) |
| AT (1) | ATE128704T1 (de) |
| AU (1) | AU621865B2 (de) |
| CA (1) | CA1337990C (de) |
| DE (1) | DE68924439T2 (de) |
| DK (1) | DK169329B1 (de) |
| ES (1) | ES2079373T3 (de) |
| FI (1) | FI891689A7 (de) |
| GR (1) | GR3017656T3 (de) |
| HU (1) | HUT50761A (de) |
| IE (1) | IE891140L (de) |
| IL (1) | IL89835A0 (de) |
| LV (1) | LV11459B (de) |
| NO (1) | NO891470L (de) |
| NZ (1) | NZ228600A (de) |
| PT (1) | PT90222B (de) |
| YU (1) | YU71489A (de) |
| ZA (1) | ZA892549B (de) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229381A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| US5229510A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | β-lactams useful in determining the amount of elastase in a clinical sample |
| IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
| GB9103654D0 (en) * | 1991-02-21 | 1991-04-10 | Merck Sharp & Dohme | Chemical process |
| US5100880A (en) * | 1991-03-20 | 1992-03-31 | Merck & Co., Inc. | Novel betalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone |
| US5104862A (en) * | 1991-03-20 | 1992-04-14 | Merck & Co., Inc. | Bethalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone |
| EP0533951A4 (en) * | 1991-04-10 | 1993-09-01 | Japan Tobacco Inc. | Novel oxazinone derivative |
| US5348953A (en) * | 1991-06-25 | 1994-09-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| WO1993000332A1 (en) | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| JP2525125B2 (ja) * | 1991-07-23 | 1996-08-14 | シェリング・コーポレーション | 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法 |
| US5688785A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5688787A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| US5276139A (en) * | 1991-08-26 | 1994-01-04 | Merck & Co., Inc. | Haptens useful in evaluating inhibition of PNN elastase by N-substituted azetidinones |
| US5274080A (en) * | 1991-08-26 | 1993-12-28 | Merck & Co., Inc. | Monospecific antibodies useful in evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones |
| EP0529719A1 (de) * | 1991-08-26 | 1993-03-03 | Merck & Co. Inc. | Test zur Bestimmung der Hemmung der PMN-Elastase durch N-substituierte Azetidinone |
| US5229267A (en) * | 1991-08-26 | 1993-07-20 | Merck & Co., Inc. | Assay for evaluating inhibition of PMN elastase by N-substituted azetidinones |
| US5149838A (en) * | 1991-09-20 | 1992-09-22 | Merck & Co., Inc. | Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents |
| GB2266527A (en) * | 1992-03-17 | 1993-11-03 | Merck & Co Inc | Substituted azetidinones useful in the treatment of leukemia |
| US5250676A (en) * | 1992-03-23 | 1993-10-05 | University Of Notre Dame Du Lac | Process for the preparation of 3-substituted-2-azetidinones |
| MY128261A (en) * | 1992-10-27 | 2007-01-31 | Merck Sharp & Dohme | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
| JPH08502752A (ja) * | 1992-10-27 | 1996-03-26 | メルク エンド カンパニー インコーポレーテッド | 抗炎症剤及び抗変性剤としての新規の置換アゼチジノン |
| AU5802894A (en) * | 1992-12-17 | 1994-07-04 | Merck & Co., Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
| US5591737A (en) * | 1992-12-17 | 1997-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| GB9314350D0 (en) * | 1993-07-12 | 1993-08-25 | Zeneca Ltd | Armide derivatives |
| US5420010A (en) * | 1993-07-30 | 1995-05-30 | Merck & Co., Inc. | Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5403952A (en) * | 1993-10-08 | 1995-04-04 | Merck & Co., Inc. | Substituted cyclic derivatives as novel antidegenerative agents |
| WO1995024207A1 (en) * | 1994-03-11 | 1995-09-14 | Merck & Co., Inc. | Composition for the treatment of lung disease |
| US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| AU5014496A (en) * | 1995-03-23 | 1996-10-08 | Japan Tobacco Inc. | Diphenylmethyl-azetidinone compounds and elastase inhibitor |
| US5747485A (en) * | 1995-04-13 | 1998-05-05 | Merck & Co., Inc. | Substituted azetidiones as anti-inflammatory and antidegenerative agents |
| US5523233A (en) * | 1995-05-03 | 1996-06-04 | Merck & Co., Inc. | Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters |
| EP0840725A1 (de) * | 1995-07-01 | 1998-05-13 | Smithkline Beecham Plc | Azetidinonderivate zur behandlung von atherosclerosis |
| WO1997013750A1 (en) * | 1995-10-09 | 1997-04-17 | Chiroscience Limited | Azetidinones and their therapeutic use as cytokine inhibitors |
| JP2000502079A (ja) * | 1995-12-08 | 2000-02-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体 |
| HUP9901359A3 (en) * | 1996-04-26 | 2000-03-28 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
| CA2301548C (en) * | 1997-10-07 | 2005-05-17 | Boehringer Ingelheim (Canada) Ltd. | Azetidinone derivatives for the treatment of hcmv infections |
| ATE224872T1 (de) * | 1997-10-07 | 2002-10-15 | Boehringer Ingelheim Ca Ltd | Azetidinonderivate zur behandlung von hcmv entzündungen |
| CA2301967C (en) * | 1997-10-07 | 2005-05-17 | Boehringer Ingelheim (Canada) Ltd. | Azetidinone derivatives for the treatment of hcmv infections |
| WO1999064395A1 (en) * | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
| US6335324B1 (en) | 1998-06-25 | 2002-01-01 | Bristol-Myers Squibb Co. | Beta lactam compounds and their use as inhibitors of tryptase |
| EP1099690A4 (de) * | 1998-07-23 | 2001-10-17 | Shionogi & Co | Monozyklische beta-lactamverbindungen und chymase inhibitoren, die diese enthalten |
| AR023463A1 (es) | 1999-04-16 | 2002-09-04 | Schering Corp | Uso de compuestos de azetidinona |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| DK1355644T3 (da) | 2001-01-26 | 2006-10-23 | Schering Corp | Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| HU230253B1 (hu) | 2001-01-26 | 2015-11-30 | Merck Sharp & Dohme Corp | Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére |
| DK1373230T3 (da) | 2001-03-28 | 2005-11-07 | Schering Corp | Enantiselektiv syntese af azetidinon mellemprodukter |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| JP2005504091A (ja) | 2001-09-21 | 2005-02-10 | シェーリング コーポレイション | ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置 |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| WO2004043457A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| CA2517571C (en) | 2003-03-07 | 2011-07-05 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
| US8440819B2 (en) * | 2008-02-22 | 2013-05-14 | Allergan, Inc. | Therapeutic substituted beta-lactams |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
-
1989
- 1989-04-04 NZ NZ228600A patent/NZ228600A/en unknown
- 1989-04-04 IL IL89835A patent/IL89835A0/xx unknown
- 1989-04-06 ES ES89200864T patent/ES2079373T3/es not_active Expired - Lifetime
- 1989-04-06 AT AT89200864T patent/ATE128704T1/de not_active IP Right Cessation
- 1989-04-06 EP EP89200864A patent/EP0337549B1/de not_active Expired - Lifetime
- 1989-04-06 DE DE68924439T patent/DE68924439T2/de not_active Expired - Fee Related
- 1989-04-07 CA CA000595997A patent/CA1337990C/en not_active Expired - Fee Related
- 1989-04-07 PT PT90222A patent/PT90222B/pt not_active IP Right Cessation
- 1989-04-07 ZA ZA892549A patent/ZA892549B/xx unknown
- 1989-04-10 HU HU891708A patent/HUT50761A/hu unknown
- 1989-04-10 YU YU00714/89A patent/YU71489A/xx unknown
- 1989-04-10 NO NO89891470A patent/NO891470L/no unknown
- 1989-04-10 FI FI891689A patent/FI891689A7/fi not_active Application Discontinuation
- 1989-04-10 CN CN89103271A patent/CN1037144A/zh active Pending
- 1989-04-10 KR KR1019890004702A patent/KR930008223B1/ko not_active Expired - Lifetime
- 1989-04-10 IE IE891140A patent/IE891140L/xx not_active IP Right Cessation
- 1989-04-10 DK DK170589A patent/DK169329B1/da not_active IP Right Cessation
- 1989-04-10 AU AU32630/89A patent/AU621865B2/en not_active Ceased
- 1989-04-11 JP JP1091723A patent/JP2736113B2/ja not_active Expired - Fee Related
-
1995
- 1995-10-05 GR GR950402512T patent/GR3017656T3/el unknown
-
1996
- 1996-02-01 LV LVP-96-24A patent/LV11459B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LV11459A (lv) | 1996-08-20 |
| EP0337549A1 (de) | 1989-10-18 |
| DK169329B1 (da) | 1994-10-10 |
| CA1337990C (en) | 1996-01-23 |
| YU71489A (en) | 1991-10-31 |
| DE68924439T2 (de) | 1996-05-09 |
| NO891470D0 (no) | 1989-04-10 |
| ATE128704T1 (de) | 1995-10-15 |
| IL89835A0 (en) | 1989-12-15 |
| ZA892549B (en) | 1989-11-29 |
| FI891689A0 (fi) | 1989-04-10 |
| DK170589D0 (da) | 1989-04-10 |
| CN1037144A (zh) | 1989-11-15 |
| DK170589A (da) | 1989-10-12 |
| DE68924439D1 (de) | 1995-11-09 |
| ES2079373T3 (es) | 1996-01-16 |
| GR3017656T3 (en) | 1996-01-31 |
| JPH026471A (ja) | 1990-01-10 |
| EP0337549B1 (de) | 1995-10-04 |
| HUT50761A (en) | 1990-03-28 |
| NZ228600A (en) | 1992-02-25 |
| PT90222B (pt) | 1994-07-29 |
| JP2736113B2 (ja) | 1998-04-02 |
| AU3263089A (en) | 1989-10-12 |
| IE891140L (en) | 1989-10-11 |
| KR930008223B1 (ko) | 1993-08-27 |
| PT90222A (pt) | 1989-11-10 |
| LV11459B (en) | 1996-12-20 |
| FI891689A7 (fi) | 1989-10-12 |
| KR900016121A (ko) | 1990-11-12 |
| AU621865B2 (en) | 1992-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO891470D0 (no) | Fremgangsmaate for fremstilling av nye substituerte azetidinoner. | |
| ES553821A0 (es) | Un procedimiento para la preparacion de nuevas azetidinonas sustituidas. | |
| NO914027D0 (no) | Fremgangsmaate for fremstilling av nye substituerte azetidinoner | |
| ES2053864T3 (es) | Derivados de acido 4-(quinolin-2-il-metoxi)fenil-acetico substituido. | |
| DK0435321T3 (da) | Nye A-nor-steroid-3-carboxylsyrederivater | |
| FI894477A7 (fi) | Menetelmä terapeuttisesti aktiivisten 7-substituoitujen 3,5-dihydroksihept-6-yynihappojen ja niiden johdannaisten valmistamiseksi ja välituotteina käyttökelpoiset yhdisteet | |
| NO170023C (no) | Analogifremgangsmaate for fremstilling av nye terapeutisk aktive alfa-glucosidaseinhibitorer | |
| IT8025488A0 (it) | Derivati di acidi 6 beta -idrossialchilpenicillanici come inibitori della beta-lattamasi. | |
| FI933213L (fi) | Nya piperidinderivat av bensimidazolin | |
| FI96030B (fi) | Menetelmä terapeuttisesti käyttökelpoisten substituoitujen tetraliinien, kromaanien ja niitä läheisesti muistuttavien yhdisteiden valmistamiseksi sekä menetelmässä käyttökelpoisia välituotteita | |
| NO874699D0 (no) | Fremgangsmaate for frenstilling av nye substituerte cefalosporin-sulfoner. | |
| MY128261A (en) | New substituted azetidinones as anti-inflammatory and antidegenerative agents | |
| NO177712C (no) | Analogifremgangsmåte for fremstilling av nye terapeutisk virksomme alkylfosfonoseriner | |
| FI893434A7 (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten sykloalkyylitiatsolijohdannaisten valmistamiseksi | |
| NO864818D0 (no) | Fremgangsmaate for fremstilling av nye terapeutisk virksomme tetrahydroisokinolinderivater. | |
| FI901550A0 (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten di-imidatsopyrimidiini- ja imidatsopyratsolopyrimidiinijohdannaisten valmistamiseksi | |
| FI900979A7 (fi) | Tulehduksenvastaisia bentsoksatsoloneja | |
| GR880100196A (el) | Υποκατεστημενα 1,3-διοξολαν-και 1,3-διοξαν-παραγωγα,μεθοδοι για την παρασκευη τους και η χρηση τους | |
| NO893006D0 (no) | Fremgangsmaate for fremstilling av nye allylaminoetylazoler | |
| FI893001A7 (fi) | Menetelmä uusien, terapeuttisesti käyttökelpoisten 1,2-bentsisoksatsol-3-yyli- ja 1,2-bentsisotiatsol-3-yylijohdannaisten valmistamiseksi |